Tessera Therapeutics
Christopher Bolt is a Senior Scientist at Tessera Therapeutics, where responsibilities include managing and delegating experiments to investigate host-cell responses during transgenesis events. Prior experience includes serving as a Senior Lecturer at the University of Geneva and as a Scientist at EPFL, where Christopher Bolt led collaborative research programs focused on engineering DNA mutations in mice and fish to explore genetic causes of congenital anomalies. Christopher Bolt holds a PhD in Cellular and Developmental Biology from the University of Illinois Urbana-Champaign and a Bachelor of Science in Cell/Cellular and Molecular Biology from Bradley University.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.